中国癌症杂志
中國癌癥雜誌
중국암증잡지
CHINA ONCOLOGY
2009年
10期
766-769
,共4页
范南峰%叶韵斌%林榕波%郭增清%周志锋%王晓杰%陈明水%陈淑萍%李洁羽%陈强
範南峰%葉韻斌%林榕波%郭增清%週誌鋒%王曉傑%陳明水%陳淑萍%李潔羽%陳彊
범남봉%협운빈%림용파%곽증청%주지봉%왕효걸%진명수%진숙평%리길우%진강
肾脏肿瘤%移植物抗宿主病%HLA部分相合%免疫治疗
腎髒腫瘤%移植物抗宿主病%HLA部分相閤%免疫治療
신장종류%이식물항숙주병%HLA부분상합%면역치료
renal-cell carcinoma%graft-versus-host disease%partially HLA-matched%immunotherapy
背景与目的:肾细胞癌是一种对免疫治疗敏感的肿瘤,包括了非清髓性异基因移植.然而由于严重的毒性,许多转移性肾细胞癌并不适合非清髓性异基因移植.这促使了其他一些新的异基因免疫治疗的发展.本研究评价输注经照射的HLA部分相合的异基因单个核细胞治疗晚期肾细胞癌的有效性和安全性.方法:选择经病理证实的晚期肾细胞癌患者,予输注经照射的HLA部分相合的异基因单个核细胞.每2个月输注1次,治疗有效或稳定者继续输注,直至疾病进展或出现不能耐受的不良反应或患者(或供者)拒绝继续使用.结果:8例患者进入本研究.6例患者每次输注后每日口服沙利度胺100 mg至300 mg两个月,1例达到持久的完全缓解(CR),5例稳定(SO),2例进展(PD).8例患者的中位疾病无进展时间为292 d,中位生存时间为879 d以上.毒性反应轻微.结论:输注经照射的HLA部分相合的异基因单个核细胞治疗晚期肾细胞癌有了一定疗效,值得进一步研究.
揹景與目的:腎細胞癌是一種對免疫治療敏感的腫瘤,包括瞭非清髓性異基因移植.然而由于嚴重的毒性,許多轉移性腎細胞癌併不適閤非清髓性異基因移植.這促使瞭其他一些新的異基因免疫治療的髮展.本研究評價輸註經照射的HLA部分相閤的異基因單箇覈細胞治療晚期腎細胞癌的有效性和安全性.方法:選擇經病理證實的晚期腎細胞癌患者,予輸註經照射的HLA部分相閤的異基因單箇覈細胞.每2箇月輸註1次,治療有效或穩定者繼續輸註,直至疾病進展或齣現不能耐受的不良反應或患者(或供者)拒絕繼續使用.結果:8例患者進入本研究.6例患者每次輸註後每日口服沙利度胺100 mg至300 mg兩箇月,1例達到持久的完全緩解(CR),5例穩定(SO),2例進展(PD).8例患者的中位疾病無進展時間為292 d,中位生存時間為879 d以上.毒性反應輕微.結論:輸註經照射的HLA部分相閤的異基因單箇覈細胞治療晚期腎細胞癌有瞭一定療效,值得進一步研究.
배경여목적:신세포암시일충대면역치료민감적종류,포괄료비청수성이기인이식.연이유우엄중적독성,허다전이성신세포암병불괄합비청수성이기인이식.저촉사료기타일사신적이기인면역치료적발전.본연구평개수주경조사적HLA부분상합적이기인단개핵세포치료만기신세포암적유효성화안전성.방법:선택경병리증실적만기신세포암환자,여수주경조사적HLA부분상합적이기인단개핵세포.매2개월수주1차,치료유효혹은정자계속수주,직지질병진전혹출현불능내수적불량반응혹환자(혹공자)거절계속사용.결과:8례환자진입본연구.6례환자매차수주후매일구복사리도알100 mg지300 mg량개월,1례체도지구적완전완해(CR),5례은정(SO),2례진전(PD).8례환자적중위질병무진전시간위292 d,중위생존시간위879 d이상.독성반응경미.결론:수주경조사적HLA부분상합적이기인단개핵세포치료만기신세포암유료일정료효,치득진일보연구.
Background and purpose: Renal-cell carcinoma (RCC) is susceptible to immune therapy including the use of the nonmyeloablative allogeneic transplantation(NAT). However, NST can produce severe toxicity, so it might not be appropriate for many patients with metastatic RCC. Other novel allogeneic immunotherapies have been designed to induce an autologous immune response directed against the malignancy. This study evaluated the efficacy and safety of infusions of partially HLA-matched irradiated allogeneic blood mononuclear cells for advanced renal-cell carcinoma. Methods: Patients with histologically proven diagnosis of advanced RCC received infusions of partially HLA-matched allogeneic blood mononuclear cells. Repeat infusions were given every 8 weeks. Treatment was continued until disease progressed, unacceptable toxicity, or patient (or donor) choice. Results: Eight patients were enrolled. After every infusion, 6 patients received an oral administration of thalidomide daily with 100-300 mg/d for 2 months. One patient had durable complete response. Five stable diseases and two progress diseases were observed. In eight patients, time to progression and survival were 320 and 879+days, respectively. Severe toxicity was not observed. Conclusion: Infusions of partially HLA-matcbed irradiated allogeneic blood mononuclear cells for advanced RCC may induce some antitumor effects and deserves further study.
